Narsoplimab

纳索利单抗

Report date: 2026/03/31 20:00:21

Base Information

Drug NameNarsoplimab
Drug Alias NameYARTEMLEAOMS-620646OMS-721OMS-00620646
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionMannan-binding lectin serine protease 2 inhibitors
TargetsMannan-binding lectin serine protease 2
Therapy Area/IndicationsC3 glomerulopathyThrombotic MicroangiopathiesAtypical Hemolytic Uremic Syndrome +[5] 
Global Approved IndicationsThrombotic Microangiopathies
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2025/12/23
Country/TerritoryCzechiaBelgiumBulgaria +[29] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesOmeros Corp
China Registration ClassN/A

Develop Information

Active CompaniesOmeros Corp
Inactive CompaniesN/A
Active IndicationsThrombotic MicroangiopathiesGlomerulonephritis, IGAHematopoietic stem cell transplantation (HSCT)
Inactive IndicationsC3 glomerulopathyAtypical Hemolytic Uremic Syndrome

Other Information

ATC CodeN/A
Related LinksKEGG